Clinical trial · Observational
Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical resection for hepatocellular carcinoma. The main questions it aims to answer are: Is hydrodissection-assisted microwave ablation safe and effective for treating hepatocellular carcinoma? How does the therapeutic effect of hydrodissection-assisted microwave ablation compare with surgical resection for hepatocellular carcinoma? Patients who receive either microwave ablation or surgical resection will Undergo a 2-year follow-up period.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Microwave Ablation Assisted by Diaphragm Hydrodissection | Procedure | — | UNRESOLVED |
| Surgical Resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Hydrodissection-assisted microwave ablation cohort
- description
- Patients with hepatocellular carcinoma receiving hydrodissection-assisted microwave ablation under routine clinical care. No study-specific intervention will be assigned by researchers.
- interventionNames
- Procedure: Microwave Ablation Assisted by Diaphragm Hydrodissection
- label
- Surgical resection cohort
- description
- Patients with hepatocellular carcinoma receiving surgical resection under routine clinical care. No study-specific intervention will be assigned by researchers.
- interventionNames
- Procedure: Surgical Resection
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- Up to 2 years after treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:Patients with Child-Pugh grade A or B liver function.Single hepatic lesion with a maximum diameter ≤ 5 cm.The lesion is located in the subphrenic region with a distance ≤ 10 mm from the right diaphragm. Exclusion Criteria:Presence of extrahepatic metastasis or other concomitant malignant tumors.Presence of severe cardiac, pulmonary, or renal dysfunction.Platelet count \< 50×10⁹/L with irreversible coagulation disorders. Patients with incomplete imaging or clinical medical data.
References
Publications (0)
Data not yet available